Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center Forge New Collaboration to Advance Future of Adult Cancer Care; Announce Plans to Build Region’s Only Free-Standing Cancer Hospital
Dana-Farber Cancer Institute (Dana-Farber) and Beth Israel Deaconess Medical Center (BIDMC) today announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.
- Dana-Farber Cancer Institute (Dana-Farber) and Beth Israel Deaconess Medical Center (BIDMC) today announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.
- Building on both Dana-Farber’s and BIDMC’s legacies of excellence in providing compassionate, world-class patient care and innovative research, the collaboration focuses exclusively on cancer care.
- While each organization will remain fully independent – including executive leadership, boards of trustees and philanthropy – the Dana-Farber Beth Israel Deaconess Cancer Collaboration leverages the expertise of both institutions.
- The proposed state-of-the-art inpatient cancer hospital will operate under the license of Dana-Farber and provide adult medical oncology care.